Preliminary report on the cost effectiveness of ventricular assist devices

Tomoyuki Takura, Shunei Kyo, Minoru Ono, Ryuji Tominaga, Shigeru Miyagawa, Yoshihisa Tanoue, Yoshiki Sawa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The aim of the present study was to perform a cost-effectiveness analysis (CEA) of ventricular assist devices (VAD) implantation surgery in the Japanese medical reimbursement system. The study group consisted of thirty-seven patients who had undergone VAD implantation surgery for dilated cardiomyopathy (n = 25; 67.6 %) or hypertrophic cardiomyopathy (n = 4; 10.8 %), and others (n = 8; 21.6 %). Quality-adjusted life years (QALYs) were calculated using the utility score and years of life. Medical reimbursement bills were chosen as cost indices. The observation period was the 12-month period after surgery. Then, the incremental cost-effectiveness ratio was calculated according to the VAD type. In addition, the prognosis after 36 months was estimated on the basis of the results obtained using the Markov chain model. The mean preoperative INTERMACS profile score was 2.35 ± 0.77. Our results showed that the utility score, which indicates the effectiveness of VAD implantation surgery, improved by 0.279 ± 0.188 (ΔQALY, p < 0.05). The cost of VAD implantation surgery was 313,282 ± 25,275 (ΔUS$/year) on the basis of medical reimbursement bills associated with therapeutic interventions. The calculated result of CEA was 364,501 ± 190,599 (ΔUS$/QALY). The improvement in the utility score was greater for implantable versus extracorporeal VADs (0.233 ± 0.534 vs. 0.371 ± 0.238) and ICER was 303,104 (ΔUS$/ΔQALY). Furthermore, when we estimated CEA for 36 months, the expected baseline value was 102,712 (US$/QALY). Therefore, VAD implantation surgery was cost effective considering the disease specificities.

Original languageEnglish
Pages (from-to)37-43
Number of pages7
JournalJournal of Artificial Organs
Volume19
Issue number1
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Heart-Assist Devices
Cost effectiveness
Quality-Adjusted Life Years
Surgery
Cost-Benefit Analysis
Costs and Cost Analysis
Costs
Markov Chains
Hypertrophic Cardiomyopathy
Dilated Cardiomyopathy
Markov processes
Observation

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering
  • Cardiology and Cardiovascular Medicine

Cite this

Preliminary report on the cost effectiveness of ventricular assist devices. / Takura, Tomoyuki; Kyo, Shunei; Ono, Minoru; Tominaga, Ryuji; Miyagawa, Shigeru; Tanoue, Yoshihisa; Sawa, Yoshiki.

In: Journal of Artificial Organs, Vol. 19, No. 1, 01.03.2016, p. 37-43.

Research output: Contribution to journalArticle

Takura, Tomoyuki ; Kyo, Shunei ; Ono, Minoru ; Tominaga, Ryuji ; Miyagawa, Shigeru ; Tanoue, Yoshihisa ; Sawa, Yoshiki. / Preliminary report on the cost effectiveness of ventricular assist devices. In: Journal of Artificial Organs. 2016 ; Vol. 19, No. 1. pp. 37-43.
@article{3feac00c8ad44e56b559047a3c726c60,
title = "Preliminary report on the cost effectiveness of ventricular assist devices",
abstract = "The aim of the present study was to perform a cost-effectiveness analysis (CEA) of ventricular assist devices (VAD) implantation surgery in the Japanese medical reimbursement system. The study group consisted of thirty-seven patients who had undergone VAD implantation surgery for dilated cardiomyopathy (n = 25; 67.6 {\%}) or hypertrophic cardiomyopathy (n = 4; 10.8 {\%}), and others (n = 8; 21.6 {\%}). Quality-adjusted life years (QALYs) were calculated using the utility score and years of life. Medical reimbursement bills were chosen as cost indices. The observation period was the 12-month period after surgery. Then, the incremental cost-effectiveness ratio was calculated according to the VAD type. In addition, the prognosis after 36 months was estimated on the basis of the results obtained using the Markov chain model. The mean preoperative INTERMACS profile score was 2.35 ± 0.77. Our results showed that the utility score, which indicates the effectiveness of VAD implantation surgery, improved by 0.279 ± 0.188 (ΔQALY, p < 0.05). The cost of VAD implantation surgery was 313,282 ± 25,275 (ΔUS$/year) on the basis of medical reimbursement bills associated with therapeutic interventions. The calculated result of CEA was 364,501 ± 190,599 (ΔUS$/QALY). The improvement in the utility score was greater for implantable versus extracorporeal VADs (0.233 ± 0.534 vs. 0.371 ± 0.238) and ICER was 303,104 (ΔUS$/ΔQALY). Furthermore, when we estimated CEA for 36 months, the expected baseline value was 102,712 (US$/QALY). Therefore, VAD implantation surgery was cost effective considering the disease specificities.",
author = "Tomoyuki Takura and Shunei Kyo and Minoru Ono and Ryuji Tominaga and Shigeru Miyagawa and Yoshihisa Tanoue and Yoshiki Sawa",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s10047-015-0858-5",
language = "English",
volume = "19",
pages = "37--43",
journal = "Journal of Artificial Organs",
issn = "1434-7229",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Preliminary report on the cost effectiveness of ventricular assist devices

AU - Takura, Tomoyuki

AU - Kyo, Shunei

AU - Ono, Minoru

AU - Tominaga, Ryuji

AU - Miyagawa, Shigeru

AU - Tanoue, Yoshihisa

AU - Sawa, Yoshiki

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The aim of the present study was to perform a cost-effectiveness analysis (CEA) of ventricular assist devices (VAD) implantation surgery in the Japanese medical reimbursement system. The study group consisted of thirty-seven patients who had undergone VAD implantation surgery for dilated cardiomyopathy (n = 25; 67.6 %) or hypertrophic cardiomyopathy (n = 4; 10.8 %), and others (n = 8; 21.6 %). Quality-adjusted life years (QALYs) were calculated using the utility score and years of life. Medical reimbursement bills were chosen as cost indices. The observation period was the 12-month period after surgery. Then, the incremental cost-effectiveness ratio was calculated according to the VAD type. In addition, the prognosis after 36 months was estimated on the basis of the results obtained using the Markov chain model. The mean preoperative INTERMACS profile score was 2.35 ± 0.77. Our results showed that the utility score, which indicates the effectiveness of VAD implantation surgery, improved by 0.279 ± 0.188 (ΔQALY, p < 0.05). The cost of VAD implantation surgery was 313,282 ± 25,275 (ΔUS$/year) on the basis of medical reimbursement bills associated with therapeutic interventions. The calculated result of CEA was 364,501 ± 190,599 (ΔUS$/QALY). The improvement in the utility score was greater for implantable versus extracorporeal VADs (0.233 ± 0.534 vs. 0.371 ± 0.238) and ICER was 303,104 (ΔUS$/ΔQALY). Furthermore, when we estimated CEA for 36 months, the expected baseline value was 102,712 (US$/QALY). Therefore, VAD implantation surgery was cost effective considering the disease specificities.

AB - The aim of the present study was to perform a cost-effectiveness analysis (CEA) of ventricular assist devices (VAD) implantation surgery in the Japanese medical reimbursement system. The study group consisted of thirty-seven patients who had undergone VAD implantation surgery for dilated cardiomyopathy (n = 25; 67.6 %) or hypertrophic cardiomyopathy (n = 4; 10.8 %), and others (n = 8; 21.6 %). Quality-adjusted life years (QALYs) were calculated using the utility score and years of life. Medical reimbursement bills were chosen as cost indices. The observation period was the 12-month period after surgery. Then, the incremental cost-effectiveness ratio was calculated according to the VAD type. In addition, the prognosis after 36 months was estimated on the basis of the results obtained using the Markov chain model. The mean preoperative INTERMACS profile score was 2.35 ± 0.77. Our results showed that the utility score, which indicates the effectiveness of VAD implantation surgery, improved by 0.279 ± 0.188 (ΔQALY, p < 0.05). The cost of VAD implantation surgery was 313,282 ± 25,275 (ΔUS$/year) on the basis of medical reimbursement bills associated with therapeutic interventions. The calculated result of CEA was 364,501 ± 190,599 (ΔUS$/QALY). The improvement in the utility score was greater for implantable versus extracorporeal VADs (0.233 ± 0.534 vs. 0.371 ± 0.238) and ICER was 303,104 (ΔUS$/ΔQALY). Furthermore, when we estimated CEA for 36 months, the expected baseline value was 102,712 (US$/QALY). Therefore, VAD implantation surgery was cost effective considering the disease specificities.

UR - http://www.scopus.com/inward/record.url?scp=84960983900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960983900&partnerID=8YFLogxK

U2 - 10.1007/s10047-015-0858-5

DO - 10.1007/s10047-015-0858-5

M3 - Article

C2 - 26242357

AN - SCOPUS:84960983900

VL - 19

SP - 37

EP - 43

JO - Journal of Artificial Organs

JF - Journal of Artificial Organs

SN - 1434-7229

IS - 1

ER -